FTFumiaki Tanaka

Fumiaki Tanaka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fumiaki Tanaka has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Long-term outcome of adipose-derived regenerative cell-enriched autologous fat transplantation for reconstruction after breast-conserving surgery for Japanese women with breast cancer

    by Shuhei Ito, Yuichiro Kai, Takaaki Masuda, Fumiaki Tanaka, Toshifumi Matsumoto, Yukio Kamohara, Hiroshi Hayakawa, Hiroaki Ueo, Hideki Iwaguro, Marc H. Hedrick, et al.


    • 1 August 2011
      • p. 62-7

    [Molecular mechanisms of generation and progression of esophageal cancer].

    by Fumiaki Tanaka, Kenji Ishikawa, Masaki Mori

  • Open Access

    Clinicopathological and biological significance of CDC28 protein kinase regulatory subunit 2 overexpression in human gastric cancer

    by Masaki Mori, Fumiaki Tanaka, Shinji Matsuzaki, Koshi Mimori, Yoshiaki Kita, Hiroshi Inoue

    CDC28 protein kinase regulatory subunit 2 (CKS2) is a cyclin-dependent kinase subunit (CKS) family member that participates in cell cycle regulation. Few studies have investigated its involvement in gastric cancer. In this study, we focused on the clinical and biological significance of CKS2 over-expression in gastric cancer. The expression of CKS2 mRNA was studied by real-time quantitative reverse transcription polymerase chain reaction, and the expression status in each tumor was examined to varify whether any correlation existed with clinical and pathological factors. In addition, an immuno-histochemical study was performed in selected samples. Moreover, we examined the impact of CKS2-siRNA in a gastric cancer cell line. A significantly higher expression of CKS2 mRNA was found in tumor tissues compared to paired normal tissues (p<0.01). Immunohistochemical analyses led to similar results. The overall five-year survival rate was significantly higher in the low CKS2 expression group (59.9%) than in the high CKS2 expression group (23.9%) (p<0.01). Univariate and multivariate analysis showed that CKS2 expression status was an independent prognostic factor (relative risk, 1.41; 95% confidence interval, 1.01-1.97; p<0.05). Moreover, the inhibition of cellular proliferation by CKS2-siRNA was observed in a gastric cancer cell line. CKS2 is one of the gastric cancer-related genes that correlates with biological aggressiveness and poor prognosis of gastric cancer. Thus, CKS2 is a possible candidate gene for diagnosis, as well as targeted molecular diagnosis and therapy in gastric cancer.


  • The Significance of PITX2 Overexpression in Human Colorectal Cancer

    by Hajime Hirose, Hideshi Ishii, Koshi Mimori, Fumiaki Tanaka, Ichiro Takemasa, Tsunekazu Mizushima, Masataka Ikeda, Hirofumi Yamamoto, Mitsugu Sekimoto, Yuichiro Doki, et al.

    The paired-like homeodomain transcription factor 2 (PITX2) gene encodes a transcription factor controlled by the WNT/Dvl/CTNNB1 and Hedgehog/TGFB pathways


  • ATP11A is a novel predictive marker for metachronous metastasis of colorectal cancer

    by Mori, Norikatsu Miyoshi, Hideshi Ishii, Koshi Mimori, Fumiaki Tanaka, Kennichi Nagai, Mamoru Uemura, Mitsugu Sekimoto, Yuichiro Doki, Masaki Mori

    The adenosine triphosphate-binding cassette transporter-homologous gene ATP11A belongs to an extended family of adenosine triphosphate-binding cassette transporters. We analysed the ATP11A gene in 7 colorectal cancer cell lines and 95 paired cases of colorectal cancer and non-cancerous regions to demonstrate the importance of ATP11A expression in colorectal cancer prognosis. ATP11A was expressed in the 7 colorectal cancer cell lines. ATP11A mRNA expression was higher in colorectal cancer tissue than in corresponding normal tissue (P<0.001). Patients with high ATP11A expression showed a poorer disease-free survival rate compared to those with low expression (P<0.001), thus indicating that increase in ATP11A expression was an independent predictor of metachronous metastasis of colorectal cancer. The present study suggests that ATP11A is a useful predictive marker of metastasis in colorectal cancer patients.


    • 1 September 2009
      • Vol. 36  (9) , 1435-41

    [Upper G.I. cancer: the esophagus and stomach. II. The current status of comprehensive gene analysis of esophageal cancer].

    by Asaya Shuto, Fumiaki Tanaka, Koshi Mimori, Hiromasa Fujita, Kazuo Shirouzu, Masaki Mori


    • 1 July 2009
      • Vol. 110  (4) , 207-12

    [Perspectives on current status and future directions for cancer stem cells theory in gastrointestinal cancer].

    by Ichiro Takemasa, Hideshi Ishii, Naotsugu Haraguchi, Koshi Mimori, Fumiaki Tanaka, Hiroaki Nagano, Mitsugu Sekimoto, Yuichiro Doki, Masaki Mori


    • 1 August 2002
      • Vol. 1  (10) , 785-94

    Effective strategy of dendritic cell-based immunotherapy for advanced tumor-bearing hosts: the critical role of Th1-dominant immunity.

    by Kohjiro Mashino, Noriaki Sadanaga, Fumiaki Tanaka, Mitsuhiko Ohta, Hiroshi Yamaguchi, Masaki Mori

    Although dendritic cell (DC)-based cancer-specific immunotherapy is a potent strategy for various types of carcinomas, few clinical studies have yielded optimal antitumor effects. Systemic immunodeficiency is observed in patients with advanced malignant disease. In this study, we explored the ability to induce antitumor immunity of the cultured monocyte-derived DCs from hosts with advanced malignant disease, using a mouse model. We found remarkable dysfunction of DCs from mice with advanced cancer, which exhibited T helper (Th)2-dominant immunity, and subsequent reduced antitumor immune response. On the other hand, we found dramatic restoration of the ability of DCs to induce optimal antitumor immune responses after systemic administration of streptococcal preparation OK-432 to the tumor-bearing mice, which induced Th1-dominant immunity. In therapeutic experiments, intratumoral injections of immature DCs from the OK-432-treated mice, designated OK-DCs, enhanced inhibition of tumor growth compared with injections of immature DCs from mice with advanced malignancies, designated T-DCs (P < 0.05), leading to significant prolongation in overall survival (P < 0.05). In analysis of cell surface antigens, antigen-presenting capability and interleukin 12 production, we showed functional skewing in T-DCs and significant restorations in OK-DCs. More CD8+ tumor-infiltrating lymphocytes were detected in the mice treated with OK-DCs; furthermore, CTL assays showed that intratumoral injection of OK-DCs induced tumor-specific immune response to spleen as great as those of N-DCs. These results suggested that Th1-dominant immunity might play a crucial role in the differentiation of DCs, and OK-432 might be useful for inducing optimal antitumor effects in DC-based immunotherapy in tumor-bearing hosts.


    • 15 May 2002
      • Vol. 62  (10) , 2937-41

    Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma.

    by Kohjiro Mashino, Noriaki Sadanaga, Hiroshi Yamaguchi, Fumiaki Tanaka, Mitsuhiko Ohta, Kenji Shibuta, Hiroshi Inoue, Masaki Mori

    The interactions of chemokine receptor CCR7 and its ligands are essential for migration of lymphocytes and dendritic cells to lymph nodes. In this study, we found that 4 of 6 (67%) gastric carcinoma cell lines tested expressed functional CCR7 for the chemokine CCL21/6Ckine, as demonstrated by calcium mobilization and actin polymerization assays. Moreover, we also showed that signaling through CCR7 induced chemotactic and invasive responses in CCR7-positive gastric carcinoma cells. In clinical samples, immunohistochemical assay showed that CCR7-positive carcinoma cells were detected in 42 of 64 (66%) cases and a significant difference in both lymph node metastasis (P < 0.001) and lymphatic invasion (P < 0.001) between CCR7-positive and -negative cases. Patients with CCR7-positive tumors had a significantly poorer prognosis than those with CCR7-negative tumors (P < 0.05). Stepwise regression analysis revealed that the most important factor related to lymph node metastasis was the expression of CCR7. These results indicated that CCR7 and its ligands interaction is associated with preferential lymph node metastasis of gastric carcinoma.


  • AMAGE-1-encoded HLA-A24-binding synthetic peptide induces specific anti-tumor cytotoxic T lymphocytes

    by Tatsuo Fujie, Kouichirou Tahara, Fumiaki Tanaka, Masaki Mori, Kazutou Takesako, Tsuyoshi Akiyoshi

    Although several MAGE-1 peptides have already been identified, the MAGE-1-encoded peptide presented by HLA-A24, which is the most common allele in Japanese population and is also frequently present in Caucasians, might have a wide applicability for immunotherapy using these peptides. To identify this potential peptide, we examined the induction of specific cytotoxic T lymphocytes (CTL) from the peripheral-blood mononuclear cells (PBMC) in HLA-A24 healthy donors by in vitro stimulation with MAGE-1-encoded synthetic peptides with a binding affinity for HLA-A24, by a simplified method. Of the 5 peptides tested, the highest HLA binder (NYKHCFPEI) was able to elicit CTL from unseparated PBMC by stimulation with freshly isolated, peptide-pulsed PMBC as antigen-presenting cells (APC) and by also using interleukin 7 and keyhole-limpet hemocyanin for a primary culture. The induced CTL could thus lyse HLA-A24 tumor cells expressing MAGE-1, as well as the peptide-pulsed target cells, in an HLA-class-I-restricted manner. By using the MAGE-1/HLA-A24 peptide, NYKHCFPEI, we found it possible to immunize many more patients, especially Japanese patients, by means of such peptide-based immunotherapeutic approaches to MAGE-1-positive malignant tumors. Int. J. Cancer 80:169–172, 1999.